Search

file (14) (1)

Investor Overview

Investor Overview

HOMEInvestor Overview

Read More

2026.Apr.24

News

OBI Announces US FDA Registration and Activation of HYProtecan™ Type II Drug Master File
Supporting Obrion Engine™ ADC Technologies and Enhancing Regulatory Efficiency

2026.Apr.16

News

OBI is featured in the Bioconjugate Insights on Bispecific and Dual-Payload ADC Design Strategies
Focusing on Approaches to Address Tumor Heterogeneity and Drug Resistance

2026.Apr.15

News

OBI Pharma Announces Ten Poster Presentations at the AACR 2026 Annual Meeting for GlycOBI® Glycan-based Site-Specific Antibody-Drug Conjugates (ADCs): Mono and Bi-Specific (inc. Dual payload) and Obrion™ ADC enabling technologies.

Read More

2026.Apr.30

Announcement

Announcement of the election of Vice Chairperson by the Company’s Board of Directors

2026.Apr.30

Announcement

Announcement on behalf of Amaran for the change of representative of its institutional director

2026.Apr.30

Announcement

Announcement of the change of representative of the Company’s institutional director, Yi Tai Investment Co., Ltd.

2024 Annual Report

Learn how we created value in 2024 and worked to pursue our purpose of enabling a healthier world.

Download PDF
Read More

Featured
Presentation

2025 Investors' Meeting - Driving Value Transformation Through ADC Innovation

Download PDF

Read More

2025 First Extraordinary General Shareholders’ Meeting

  • 2025.Oct.20 at 09:00 AM
  • Taipei Bioinnovation Park 1F Conference Room
Youtube

Governance

Read More

Corporate
Overview​

Board of
Directors​

Special ​
Committee​

Integrity​

Internal
Audit​

Governance
Document​

Investor Relations

Contact